The Pathophysiology of Moyamoya Disease: An Update

키워드

참고문헌 (85)

1. Scott RM, "Moyamoya disease and moyamoya syndrome", N Engl J Med, 360, pp.1226~1237 (2009)
2. Fukui M, "Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of willis (‘moyamoya’ disease). Research committee on spontaneous occlusion of the circle of willis (moyamoya disease) of the ministry of health and welfare, japan", Clin Neurol Neurosurg, 99(Suppl 2), pp.S238~S240 (1997)
3. Bang OY, "Adult moyamoya disease: a burden of intracranial stenosis in east asians?", PLoS One, 10, pp.e0130663~ (2015)
4. Suzuki J, "Cerebrovascular “moyamoya” disease. Disease showing abnormal net-like vessels in base of brain", Arch Neurol, 20, pp.288~299 (1969)
5. Kuroda S, "Moyamoya disease : current concepts and future perspectives", Lancet Neurol, 7, pp.1056~1066 (2008)
6. Takagi Y, "Histological features of middle cerebral arteries from patients treated for moyamoya disease", Neurol Med Chir, 47, pp.1~4 (2007)
7. Oka K, "Cerebral haemorrhage in moyamoya disease at autopsy", Virchows Archiv. A, Pathological Anatomy and Histology, 392, pp.247~261 (1981)
8. Chmelova J, "Moyamoya disease is associated with endothelial activity detected by anti-nestin antibody", Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 154, pp.159~162 (2010)
9. Lin R, "Clinical and immunopathological features of moyamoya disease", PLoS One, 7, pp.e36386~ (2012)
10. Takagi Y, "Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with moyamoya disease", Neurosurgery, 60, pp.338~345 (2007)
11. Kaku Y, "Outer-diameter narrowing of the internal carotid and middle cerebral arteries in moyamoya disease detected on 3d constructive interference in steady-state mr image: is arterial constrictive remodeling a major pathogenesis?", Acta Neurochir, 154, pp.2151~2157 (2012)
12. Kim YJ, "High resolution mri difference between moyamoya disease and intracranial atherosclerosis", Eur J Neurol, 20, pp.1311~1318 (2013)
13. Ryoo S, "Highresolution magnetic resonance wall imaging findings of moyamoya disease", Stroke, 45, pp.2457~2460 (2014)
14. Yuan M, "High-resolution mr imaging of the arterial wall in moyamoya disease", Neurosci Lett, 584, pp.77~82 (2015)
15. Guo DC, "Mutations in smooth muscle alpha-actin (acta2) cause coronary artery disease, stroke, and moyamoya disease, along with thoracic aortic disease", Am J Hum Genet, 84, pp.617~627 (2009)
16. Fukui M, "Moyamoya disease", Neuropathology, 20(Suppl), pp.S61~S64 (2000)
17. Czabanka M, "Characterization of cortical microvascularization in adult moyamoya disease", Stroke, 39, pp.1703~1709 (2008)
18. Kim SJ, "Neovascularization precedes occlusion in moyamoya disease : angiographic findings in 172 pediatric patients", Eur Neurol, 72, pp.299~305 (2014)
19. Ikeda H, "Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26", Am J Hum Genet, 64, pp.533~537 (1999)
20. Inoue TK, "Linkage analysis of moyamoya disease on chromosome 6", J Child Neurol, 15, pp.179~182 (2000)
21. Sakurai K, "A novel susceptibility locus for moyamoya disease on chromosome 8q23", J Hum Genet, 49, pp.278~281 (2004)
22. Yamauchi T, "Linkage of familial moyamoya disease(spontaneous occlusion of the circle of willis)to chromosome 17q25", Stroke, 31, pp.930~935 (2000)
23. Kamada F, "A genome-wide association study identifies rnf213 as the first moyamoya disease gene", J Hum Genet, 56, pp.34~40 (2011)
24. Liu W, "Identification of rnf213 as a susceptibility gene for moyamoya disease and its possible role in vascular development", PLoS One, 6, pp.e22542~ (2011)
25. Miyatake S, "Homozygous c.14576g>a variant of rnf213predicts early-onset and severe form of moyamoya disease", Neurology, 78, pp.803~810 (2012)
26. Kim EH, "Importance of rnf213 polymorphism on clinical features and longterm outcome in moyamoya disease", J Neurosurg, pp.1~7 (2015)
27. Liu W, "Distribution of moyamoya disease susceptibility polymorphism p.R4810k in rnf213 in east and southeast asian populations", Neurol Med Chir, 52, pp.299~303 (2012)
28. Liu W, "A rare asian founder polymorphism of raptor may explain the high prevalence of moyamoya disease among east asians and its low prevalence among caucasians", Environmental Health and Preventive Medicine, 15, pp.94~104 (2010)
29. Cecchi AC, "Rnf213 rare variants in an ethnically diverse population with moyamoya disease", Stroke, 45, pp.3200~3207 (2014)
30. Wu Z, "Molecular analysis of rnf213 gene for moyamoya disease in the chinese han population", PLoS One, 7, pp.e48179~ (2012)
31. Ma J, "Rnf213 polymorphism and moyamoya disease : a systematic review and metaanalysis", Neurology India, 61, pp.35~39 (2013)
32. Kleinloog R, "Regional differences in incidence and patient characteristics of moyamoya disease : a systematic review", J Neurol Neurosurg Psychiatry, 83, pp.531~536 (2012)
33. Sonobe S, "Temporal profile of the vascular anatomy evaluated by 9.4-t magnetic resonance angiography and histopathological analysis in mice lacking rnf213: a susceptibility gene for moyamoya disease", Brain Res, 1552, pp.64~71 (2014)
34. Kanoke A, "Temporal profile of the vascular anatomy evaluated by 9.4-tesla magnetic resonance angiography and histological analysis in mice with the r4859k mutation of rnf213, the susceptibility gene for moyamoya disease", Brain Research, 1624, pp.497~505 (2015)
35. Miki Fujimura, "Genetics and Biomarkers of Moyamoya Disease: Significance of RNF213 as a Susceptibility Gene", 대한뇌졸중학회지, 16(2), pp.65~72 (2014), 대한뇌졸중학회[DOI]
36. Ito A, "Enhanced post-ischemic angiogenesis in mice lacking rnf213; a susceptibility gene for moyamoya disease", Brain Res, 1594, pp.310~320 (2015)
37. Hitomi T, "Downregulation of securin by the variant rnf213r4810k (rs112735431, g>a) reduces angiogenic activity of in duced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients", Biochem Biophys Res Commun, 438, pp.13~19 (2013)
38. Kobayashi H, "Biochemical and functional characterization of rnf213 (mysterin) r4810k, a susceptibility mutation of moyamoya disease, in angiogenesis in vitro and in vivo", J Am Heart Assoc, 4, pp.e002146~ (2015)
39. Ohkubo K, "Moyamoya disease susceptibility gene rnf213 links inflammatory and angiogenic signals in endothelial cells", Sci Rep, 5, pp.13191~ (2015)
40. Kim SJ, "Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease : A prospective study", Stroke, 41, pp.173~176 (2010)
41. Bower RS, "Moyamoya disease in a primarily white, midwestern us population: increased prevalence of autoimmune disease", Stroke, 44, pp.1997~1999 (2013)
42. Li H, "Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease : a case-control study", Stroke, 42, pp.1138~1139 (2011)
43. Koizumi A, "P.R4810k, a polymorphism of rnf213, the susceptibility gene for moyamoya disease, is associated with blood pressure", Environ Health Prev Med, 18, pp.121~129 (2013)
44. Bartel DP, "Micrornas: genomics, biogenesis, mechanism, and function", Cell, 116, pp.281~297 (2004)
45. Liu P, "Microrna-424 protects against focal cerebral ischemia and reperfusion injury in mice by suppressing oxidative stress", Stroke, 46, pp.513~519 (2015)
46. De Rosa S, "Emerging role of micrornas in cardiovascular diseases", Circulation Journal : Official Journal of the Japanese Circulation Society, 78, pp.567~575 (2014)
47. Koutsis G, "The emerging role of microrna in stroke", Current Topics in Medicinal Chemistry, 13, pp.1573~1588 (2013)
48. Zeng L, "Microrna-210 overexpression induces angiogenesis and neurogenesis in the normal adult mouse brain", Gene Therapy, 21, pp.37~43 (2014)
49. Dai D, "Serum mirna signature in moyamoya disease", PLoS One, 9, pp.e102382~ (2014)
50. Park YS, "Association of the mir-146ac>g, mir-196a2c>t, and mir-499a>g polymorphisms with moyamoya disease in the korean population", Neurosci Lett, 521, pp.71~75 (2012)
51. Eberhard DA, "Alterations of annexin expression in pathological neuronal and glial reactions. Immunohistochemical localization of annexins i, ii (p36 and p11 subunits), iv, and vi in the human hippocampus", Am J Pathol, 145, pp.640~649 (1994)
52. Herbert SP, "The confluence-dependent interaction of cytosolic phospholipase a2-alpha with annexin a1 regulates endothelial cell prostaglandin e2 generation", J Biol Chem, 282, pp.34468~34478 (2007)
53. Kumar AH, "Clinical potential of adult vascular progenitor cells", Arterioscler Thromb Vasc Biol, 30, pp.1080~1087 (2010)
54. Yoshihara T, "Increase in circulating cd34-positive cells in patients with angiographic evidence of moyamoya-like vessels", J Cereb Blood Flow Metab, 28, pp.1086~1089 (2008)
55. Rafat N, "Increased levels of circulating endothelial progenitor cells in patients with moyamoya disease", Stroke, 40, pp.432~438 (2009)
56. Kim JH, "Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease", J Neurosci Res, 88, pp.510~518 (2010)
57. Jung KH, "Circulating endothelial progenitor cells as a pathogenetic marker of moyamoya disease", J Cereb Blood Flow Metab, 28, pp.1795~1803 (2008)
58. Lee JY, "Deregulation of retinaldehyde dehydrogenase 2 leads to defective angiogenic function of endothelial colony-forming cells in pediatric moyamoya disease", Arterioscler Thromb Vasc Biol, 35, pp.1670~1677 (2015)
59. Kang HS, "Smooth-muscle progenitor cells isolated from patients with moyamoya disease : Novel experimental cell model", J Neurosurg, 120, pp.415~425 (2014)
60. Kang HS, "Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya disease", J Neurol Neurosurg Psychiatry, 81, pp.673~678 (2010)
61. Nanba R, "Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in moyamoya disease", Stroke, 35, pp.2837~2842 (2004)
62. Park YS, "The role of vegf and kdr polymorphisms in moyamoya disease and collateral revascularization", PLoS One, 7, pp.e47158~ (2012)
63. Kim SK, "Elevation of crabp-i in the cerebrospinal fluid of patients with moyamoya disease", Stroke, 34, pp.2835~2841 (2003)
64. Fujimura M, "Increased expression of serum matrix metalloproteinase-9in patients with moyamoya disease", Surg Neurol, 72, pp.476~480 (2009)
65. Kang HS, "Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease", Neurosurgery, 58, pp.1074~1080 (2006)
66. He J, "Expression of circulating vascular endothelial growth factor-antagonizing cytokines and vascular stabilizing factors prior to and following bypass surgery in patients with moyamoya disease", Exp Ther Med, 8, pp.302~308 (2014)
67. Hoshimaru M, "Possible roles of basic fibroblast growth factor in the pathogenesis of moyamoya disease : an immunohistochemical study", J Neurosurg, 75, pp.267~270 (1991)
68. Park YS, "The role of vegf and kdr polymorphisms in moyamoya disease and collateral revascularization", PLoS One, 7, pp.e47158~ (2012)
69. Wang X, "Impacts and interactions of pdgfrb, mmp-3, timp-2, and rnf213polymorphisms on the risk of moyamoya disease in han chinese human subjects", Gene, 526, pp.437~442 (2013)
70. Young AM, "Is there a role for treating inflammation in moyamoya disease?: a review of histopathology, genetics, and signaling cascades", Frontiers in Neurology, 4, pp.105~ (2013)
71. Jeon JS, "Expression of cellular retinoic acid-binding protein-i(crabp-i)in the cerebrospinal fluid of adult onset moyamoya disease and its association with clinical presentation and postoperative haemodynamic change", J Neurol Neurosurg Psychiatry, 85, pp.726~731 (2014)
72. Soriano SG, "Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome", Neurosurgery, 50, pp.544~549 (2002)
73. Noda A, "Elevation of nitric oxide metabolites in the cerebrospinal fluid of patients with moyamoya disease", Acta Neurochirurgica, 142, pp.1275~1279 (2000)
74. Park YS, "Age-specific enos polymorphisms in moyamoya disease", Childs Nerv Syst, 27, pp.1919~1926 (2011)
75. Frank PG, "Caveolin, caveolae, and endothelial cell function", Arterioscler Thromb Vasc Biol, 23, pp.1161~1168 (2003)
76. Liu J, "Caveolin-1 expression enhances endothelial capillary tubule formation", The Journal of Biological Chemistry, 277, pp.10661~10668 (2002)
77. Chang SH, "Vascular permeability and pathological angiogenesis in caveolin-1-null mice", The American Journal of Pathology, 175, pp.1768~1776 (2009)
78. Sonveaux P, "Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis", Circulation Research, 95, pp.154~161 (2004)
79. Morais C, "Altered angiogenesis in caveolin-1 gene-deficient mice is restored by ablation of endothelial nitric oxide synthase", The American Journal of Pathology, 180, pp.1702~1714 (2012)
80. Sbaa E, "Caveolin plays a central role in endothelial progenitor cell mobilization and homing in sdf-1-driven postischemic vasculogenesis", Circulation Research, 98, pp.1219~1227 (2006)
81. Navarro G, "Potential of caveolae in the therapy of cardiovascular and neurological diseases", Frontiers in Physiology, 5, pp.370~ (2014)
82. Jasmin JF, "Caveolin-1 deficiency increases cerebral ischemic injury", Circulation Research, 100, pp.721~729 (2007)
83. Xu L, "Caveolae : Molecular insights and therapeutic targets for stroke", Expert Opin Ther Targets, 19, pp.633~650 (2015)
84. iodoamphetamine single-photon emission computed tomography, "Neurosurgery", 2011, 957~964
85. Bang OY, "Collateral circulation in ischemic stroke : Assessment tools and therapeutic strategies", Stroke, 46, pp.3302~3309 (2015)

관련 논문AI추천